1. Home
  2. AMCX vs CLLS Comparison

AMCX vs CLLS Comparison

Compare AMCX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

SELL

Current Price

$10.27

Market Cap

492.0M

ML Signal

SELL

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$1.04

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
CLLS
Founded
1980
1999
Country
United States
France
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
492.0M
394.4M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
AMCX
CLLS
Price
$10.27
$1.04
Analyst Decision
Sell
Buy
Analyst Count
8
5
Target Price
★ $9.67
$4.83
AVG Volume (30 Days)
★ 596.2K
90.5K
Earning Date
11-06-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 132.55
N/A
EPS
N/A
★ N/A
Revenue
★ $2,311,801,000.00
N/A
Revenue This Year
$5.07
N/A
Revenue Next Year
N/A
$10.70
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.47
$1.09
52 Week High
$12.93
$5.45

Technical Indicators

Market Signals
Indicator
AMCX
CLLS
Relative Strength Index (RSI) 29.14 18.81
Support Level $9.23 N/A
Resistance Level $10.58 $2.99
Average True Range (ATR) 0.39 0.07
MACD -0.08 0.02
Stochastic Oscillator 6.76 1.02

Price Performance

Historical Comparison
AMCX
CLLS

About AMCX AMC Networks Inc.

AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: